tirzepatide cvot New SURPASS-CVOT Ad Hoc Analysis: Tirzepatide outperforms dulaglutide for reducing cardiorenal risks in T2D patients : r/Zepbound

In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%

23.33

★★★★☆4.8 (126)

Post hoc analysis of SURPASS-CVOT trial: Tirzepatide was associated with a lower risk of the 6-component cardiorenal endpoint, driven by reduction in all-cause mortality, compared to dulaglutide in patients with T2D and

20.78

★★★★★4.9 (98)

Diabetes Distilled: SURPASS-CVOT – Tirzepatide demonstrates cardiovascular benefit in secondary prevention

20.07

★★★★★5.0 (157)

Tirzepatide vs Dulaglutide for Cardiovascular Outcomes (SURPASS-CVOT) | NEJM

23.75

★★★★★4.7 (84)

💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that tirzepatide was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What

29.43

★★★★★4.9 (203)

SURPASS-CVOT trial: Tirzepatide was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I

20.25

★★★★★5.0 (176)

Tirzepatide CV Safety Comparable to Dulaglutide in SURPASS-CVOT | Paramesh Shamanna posted on the topic

28.18

★★★★★4.8 (132)